Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Qamraa H. Alqahtani"'
Autor:
Ahlam M. Alhusaini, Hanan K. Alghibiwi, Wedad S. Sarawi, Juman S. Alsaab, Samiyah M. Alshehri, Qamraa H. Alqahtani, Aliah R. Alshanwani, Ebtesam A. Aljassas, Ebtesam N. Alsultan, Iman H. Hasan
Publikováno v:
Dose-Response, Vol 22 (2024)
Isoproterenol (ISO), a chemically synthesized catecholamine, belongs to β-adrenoceptor agonist used to treat bradycardia. The β-adrenergic agonist is an essential regulator of myocardial metabolism and contractility; however, excessive exposure to
Externí odkaz:
https://doaj.org/article/f7023449ef8a4ce189272c484977cad6
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 10, Pp 101752- (2023)
Objectives: Acetaminophen (APAP)-induced nephrotoxicity is detrimental consequence for which there has not been a standardized therapeutic regimen. Although, N-acetylcysteine (NAC) is a well-known antidote used in APAP-induced hepatotoxicity, its ben
Externí odkaz:
https://doaj.org/article/ac504dbe26e84597bdb44d6e7402de93
Autor:
Qamraa H. Alqahtani, Samiyah Alshehri, Ahlam M. Alhusaini, Wedad S. Sarawi, Sana S. Alqarni, Raessa Mohamed, Meha N. Kumar, Juman Al-Saab, Iman H. Hasan
Publikováno v:
Diseases, Vol 11, Iss 4, p 184 (2023)
Diabetes is a ubiquitous disease that causes several complications. It is associated with insulin resistance, which affects the metabolism of proteins, carbohydrates, and fats and triggers liver diseases such as fatty liver disease, steatohepatitis,
Externí odkaz:
https://doaj.org/article/1f9919e79516440db79e90d2e033e6c6
Autor:
Ahmed Z. Alanazi, Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Aljerian, Mohammad M. Algahtani, Qamraa H. Alqahtani, Dhanush Haspula, Abdullah S. Alhamed, Mohammed Alqinyah, Mohammad Raish
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 921 (2023)
Dasatinib (DASA) is a novel tyrosine kinase inhibitor, approved for leukemia treatment. However, the long-term use of DASA induces several complications, especially liver damage. On the other hand, Naringenin (NGN) is a potent antioxidant and anti-in
Externí odkaz:
https://doaj.org/article/671e7d1387084c2bbfeb0d8b8993df42
Autor:
Ahlam M. Alhusaini, Abeer M. Alanazi, Laila M. Fadda, Qamraa H. Alqahtani, Wedad S. Sarawi, Iman H. Hasan
Publikováno v:
Journal of King Saud University: Science, Vol 33, Iss 8, Pp 101640- (2021)
Objectives: Doxorubicin (DOXR) belongs to the antineoplastic anthracycline antibiotic and despite its prevalent use for various types of cancer, it is associated with side effects that occur even after treatment cessation, particularly on the heart,
Externí odkaz:
https://doaj.org/article/e7b4f8b1900643a0945d6106ac0f70c4
Autor:
Rehab A. Alshammari, Fadilah S. Aleanizy, Amal Aldarwesh, Fulwah Y. Alqahtani, Wael A. Mahdi, Bushra Alquadeib, Qamraa H. Alqahtani, Nazrul Haq, Faiyaz Shakeel, Hosam G. Abdelhady, Ibrahim A. Alsarra
Publikováno v:
Pharmaceutics, Vol 14, Iss 7, p 1444 (2022)
Ruboxistaurin (RBX) is an anti-vascular endothelial growth factor (anti-VEGF) agent that is used in the treatment of diabetic retinopathy and is mainly given intravitreally. To provide a safe and effective method for RBX administration, this study wa
Externí odkaz:
https://doaj.org/article/80ae7dd0535947c6b22dff2ca99a5d7d
Autor:
Raish, Ahmed Z. Alanazi, Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Aljerian, Mohammad M. Algahtani, Qamraa H. Alqahtani, Dhanush Haspula, Abdullah S. Alhamed, Mohammed Alqinyah, Mohammad
Publikováno v:
Pharmaceuticals; Volume 16; Issue 7; Pages: 921
Dasatinib (DASA) is a novel tyrosine kinase inhibitor, approved for leukemia treatment. However, the long-term use of DASA induces several complications, especially liver damage. On the other hand, Naringenin (NGN) is a potent antioxidant and anti-in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::66a38189170ec842f41b2c5ebcdc990e
Autor:
Alhusaini, Ahlam M.1 (AUTHOR), Alghibiwi, Hanan K.1 (AUTHOR) halghibiwi@ksu.edu.sa, Sarawi, Wedad S.1 (AUTHOR), Alsaab, Juman S.1 (AUTHOR), Alshehri, Samiyah M.1 (AUTHOR), Alqahtani, Qamraa H.1 (AUTHOR), Alshanwani, Aliah R.2 (AUTHOR), Aljassas, Ebtesam A.3 (AUTHOR), Alsultan, Ebtesam N.3 (AUTHOR), Hasan, Iman H.1 (AUTHOR)
Publikováno v:
Dose-Response. Apr-Jun2024, Vol. 22 Issue 2, p1-11. 11p.
Autor:
Alanazi, Ahmed Z.1 (AUTHOR) azalanazi@ksu.edu.sa, Alhazzani, Khalid1 (AUTHOR) 441106211@student.ksu.edu.sa, Alrewily, Salah Q.1 (AUTHOR) mohmalgahtani@ksu.edu.sa, Aljerian, Khaldoon2 (AUTHOR) kaljerian@ksu.edu.sa, Algahtani, Mohammad M.1 (AUTHOR) ghamad@ksu.edu.sa, Alqahtani, Qamraa H.1 (AUTHOR) asalhamed@ksu.edu.sa, Haspula, Dhanush3 (AUTHOR) dhanush.haspulagiridhar@nih.gov, Alhamed, Abdullah S.1 (AUTHOR) malqinyah@ksu.edu.sa, Alqinyah, Mohammed1 (AUTHOR), Raish, Mohammad4 (AUTHOR) mraish@ksu.edu.sa
Publikováno v:
Pharmaceuticals (14248247). Jul2023, Vol. 16 Issue 7, p921. 16p.
Autor:
Alshammari, Rehab A.1,2 (AUTHOR) fyalqahtani@ksu.edu.sa, Aleanizy, Fadilah S.2 (AUTHOR) faleanizy@ksu.edu.sa, Aldarwesh, Amal3 (AUTHOR) aaldarweesh@ksu.edu.sa, Alqahtani, Fulwah Y.2 (AUTHOR) bquadeib@ksu.edu.sa, Mahdi, Wael A.2 (AUTHOR) nazrulhaq59@gmail.com, Alquadeib, Bushra2 (AUTHOR) faiyazs@fastmail.fm, Alqahtani, Qamraa H.4 (AUTHOR) ghamad@ksu.edu.sa, Haq, Nazrul2 (AUTHOR) ialsarra@ksu.edu.sa, Shakeel, Faiyaz2 (AUTHOR), Abdelhady, Hosam G.5 (AUTHOR) hosam.abdelhady@shsu.edu, Alsarra, Ibrahim A.2 (AUTHOR)
Publikováno v:
Pharmaceutics. Jul2022, Vol. 14 Issue 7, pN.PAG-N.PAG. 21p.